Comparable efficacy of venetoclax 50mg with posaconazole versus venetoclax 400mg in newly diagnosed AML patients: A prospective study of pharmacokinetics, toxicity, and clinical outcomes. Detection of ...
In oncology drug development, biomarker-driven studies are pivotal, enabling the selection of patient populations most likely to benefit from specific therapeutic interventions. These studies have ...
EORTC QLQ-C30 subgroup results confirm broad and durable quality-of-life improvements across disease stages and metastasis status, complementing previously reported pain reduction and opioid-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results